Bayer shared more data on its menopause symptom drug elinzanetant, which demonstrates how the treatment triumphed over placebo in two of three Phase 3 trials.
In the placebo-controlled OASIS 1 trial, the non-hormonal therapy reduced the frequency of moderate to severe vasomotor symptoms (VMS), also known as hot flashes, at weeks 4 and 12, earning p-values of p<0.0001 and p<0.0001, respectively. It also eased the severity of the hot flashes over the same time periods.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.